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ttp://dx.doi.org/10.1016/j.ajpath.2013.06.015Alport syndrome, hereditary glomerulonephritis with hearing loss, results from mutations in type IV
collagen COL4A3, COL4A4, or COL4A5 genes. The mechanism for delayed glomerular disease onset is
unknown. Comparative analysis of Alport mice and CD151 knockout mice revealed progressive accu-
mulation of laminin 211 in the glomerular basement membrane. We show mesangial processes invading
the capillary loops of both models as well as in human Alport glomeruli, as the likely source of this
laminin. L-NAME salteinduced hypertension accelerated mesangial cell process invasion. Cultured
mesangial cells showed reduced migratory potential when treated with either integrin-linked kinase
inhibitor or Rac1 inhibitor, or by deletion of integrin a1. Treatment of Alport mice with Rac1 inhibitor
or deletion of integrin a1 reduced mesangial cell process invasion of the glomerular capillary tuft.
Laminin a2edeﬁcient Alport mice show reduced mesangial process invasion, and cultured laminin a2e
null cells showed reduced migratory potential, indicating a functional role for mesangial laminins in
progression of Alport glomerular pathogenesis. Collectively, these ﬁndings predict a role for biome-
chanical insult in the induction of integrin a1b1edependent Rac1-mediated mesangial cell process
invasion of the glomerular capillary tuft as an initiation mechanism of Alport glomerular pathology.
(Am J Pathol 2013, 183: 1269e1280; http://dx.doi.org/10.1016/j.ajpath.2013.06.015)Supported by NIH grant R01 DK055000. Confocal microscopy was
conducted at the Integrative Biological Imaging Facility, Creighton
University, Omaha, NE (supported by 5P20RR016469, National Center for
Research Resources, NIH, and 8P20GM103427, National Institute of
General Medical Sciences, NIH).Alport syndrome is characterized by delayed-onset progres-
sive glomerulonephritis associated with sensorineural
hearing loss and retinal ﬂecks.1 The most common form
(80%) is X-linked and caused by mutations in the type IV
collagen COL4A5 gene.2 The two autosomal forms of the
disease account for the remaining 20% of Alport patients, and
result from mutations in the COL4A3 and COL4A4 genes.3
The a3(IV), a4(IV), and a5(IV) proteins form a hetero-
trimer that is assembled into a subepithelial network in the
glomerular basement membrane (GBM) that is physically
and biochemically distinct from a subendothelial type IV
collagen network comprising a1(IV) and a2(IV) hetero-
trimers.4 Mutations in any one of the three type IV collagen
genes that cause Alport syndrome result in the absence of all
three proteins in the GBM due to an obligatory association to
form functional heterotrimers.5 Thus, the net result for all
genetic forms of Alport syndrome is the absence of the
a3(IV) a4(IV) a5(IV) subepithelial collagen network,
resulting in a GBM type IV collagen network comprising
only a1(IV) and a2(IV) heterotrimers.stigative Pathology.
.This change in basement membrane composition does not
result in immediate pathology. The GBM appears to func-
tion adequately for the ﬁrst few years of life and sometimes
past the ﬁrst decade.6 This delayed onset predicts a trig-
gering mechanism for glomerular disease initiation and
a theoretical window for therapeutic intervention that may
arrest or signiﬁcantly ameliorate Alport renal disease in its
earliest stages. The activation of genes encoding GBM
matrix molecules, matrix metalloproteinases (MMPs), and
proinﬂammatory cytokines have all been linked to the
progression of Alport glomerular disease. These, however,
are events that occur after the onset of proteinuria, and
therefore, downstream of disease initiation events.7e11
Consistent with this notion, experiments aimed at blocking
Zallocchi et althese pathways have offered only limited therapeutic beneﬁt
in mouse models for Alport syndrome.8e10,12 One of the
earliest events we have documented is the appearance of an
irregular deposition of laminin 211 in the GBM of Alport
mice,8 an observation conﬁrmed in both Alport dogs and
human patients with the disease.13 This laminin is normally
found only in the mesangium of the glomerulus, and is not
expressed in the GBM at any stage of embryonic develop-
ment.14 Indeed, several other mesangial matrix proteins
appear in the GBM of Alport mice, including laminin 111
and ﬁbronectin.15,16
In the Alport glomerulus, the podocytes are exposed to
GBM that has an embryonic type IV collagen composi-
tion.17,18 This could result in altered cell signaling that may
trigger the onset of the disease. It has been proposed that this
type of mechanismmay account for the reactivation of laminin
111 expression in podocytes,19 because laminin 111 is found
in the GBM during development.14 Because the a1(IV)/
a2(IV) collagen network contains signiﬁcantly fewer inter-
chain disulﬁde crosslinks,20 and the Alport GBM is thinner
than normal,21 the Alport GBM is likely to be more elastic,
resulting in elevated biomechanical strain on the glomerular
cells at their points of contact with the GBM. Consistently,
glomeruli fromAlport mice have been shown to have elevated
deformability relative to wild-type glomeruli,22 and salt-
induced hypertension has been shown to accelerate glomer-
ular disease progression in Alport mice.23
In this work, we show that the cellular origin of GBM
laminin 211 in Alport glomeruli is mesangial cell process
invasion, and that deletion of laminin 211 in Alport mice
ameliorates the mesangial process invasion of the glomer-
ular capillary loops in Alport mice. Salt-mediated hyper-
tension exacerbates this mesangial process invasion. A
knockout mouse for the integrin a3b1 coreceptor CD151
also develops mesangial process invasion of the capillary
loops with GBM deposition of laminin 211, demonstrating
the same phenotype for a completely unrelated component
of the capillary structural barrier. The CD151 knockout
mouse model also shows accelerated glomerular disease
progression in response to hypertension.24 We show that
biomechanical stretching of cultured mesangial cells
induces promigratory cytokines transforming growth
factor-b1 (TGF-b1) and connective tissue growth factor
(CTGF), both known to be induced in Alport glomeruli.7,12
Inhibitor studies indicate that mesangial cell migration is
mediated by integrin a1b1 signaling through the Rho
GTPases RAC1 and CDC42. Consistently, integrin a1
deletion in Alport mice was previously shown to ameliorate
glomerular disease progression and slow the accumulation
of laminin 211 in Alport GBM.8 Here, we show that
mesangial process invasion of the capillary loops is
ameliorated in integrin a1enull Alport mice. These data
deﬁne a role for biomechanical strain-mediated induction of
mesangial cell process invasion as a key aspect of Alport
glomerular disease initiation, and set the stage for deﬁning
novel therapeutic targets aimed at blocking this process.1270Materials and Methods
Mice
All mice used in these studies were on pure genetic back-
grounds. Autosomal recessive Alport mice were on 129/Sv
background and developed in our laboratory.15 X-linked
Alport mice were on C57Bl/6 background (acquired from
Jackson Laboratories, Bar Harbor, ME), laminin a2edeﬁcient
mice were on 129/Sv background (acquired from Jackson
Laboratories), integrin a1enull mice were on 129/Sv back-
ground,25 and CD151 knockout mice were on FVB back-
ground.26 All experiments were performed using strain/
age-matched control mice. All animal studies were conduct-
ed in accordance with standards approved by the US Depart-
ment of Agriculture and under the approval of the institutional
animal care and use committee. Every effort was made to
minimize pain and discomfort.
L-NAME Hypertension
Nu-nitro-L-arginine methyl ester (L-NAME; Sigma-Aldrich,
St. Louis, MO) salteinduced hypertension was performed
as previously described.23 Wild-type and X-linked Alport
mice on C57Bl/6 background were given L-NAME salts at
a concentration of 36 mg/100 mL of water (50 mg/kg/day)
from 5 to 10 weeks of age. Blood pressure was monitored
on a weekly basis using a CODA2 (Kent Scientiﬁc, Tor-
rington, CT) noninvasive tail cuff monitoring system.
Treatment of Mice with Rac1 Inhibitor
129/Sv autosomal Alport mice and age/strain-matched wild-
type mice were injected i.p. once daily with 2 mg/kg of the
Rac1 inhibitor NSC 23766 (Tocris Bioscience, Ellisville,
MO). Animals were treated from 2 weeks of age until 6
weeks of age.
Immunoﬂuorescence Microscopy
Fresh frozen kidneys were sectioned at 8 mm and acetone
ﬁxed. Sections were incubated overnight at 4C with 0.3%
PBST (Triton X-100), 5% fetal bovine serum, and with two
of the following antibodies: rat anti-mouse laminin a2
antibody (Sigma-Aldrich) at 1:200, goat anti-mouse integ-
rin a8 antibody (R & D Systems, Minneapolis, MN) at
1:100, rabbit anti-mouse laminin a5 antibody (a generous
gift from Dr. Jeff Miner, Washington University) at 1:200,
rabbit anti-human laminin a5 antibody (GeneTex, Irvine,
CA) at 1:500. Slides were rinsed with 1 PBS and incu-
bated with the appropriate Alexa Fluor donkey secondary
antibodies at 1:300 for 1 hour at room temperature. They
were then rinsed again with 1 PBS and mounted with
Vectashield Mounting Medium with DAPI (Vector Labo-
ratories, Burlingame, CA). De-identiﬁed human Alport
renal necropsy tissue was a gift from Dr. Raghu Kalluri and
described previously.9ajp.amjpathol.org - The American Journal of Pathology
Mesangial Processes in Alport PathologyTransmission Electron Microscopy
Transmission electron microscopy was performed as
described previously.8
Mesangial Cell Migration
Primary mesangial cell cultures were prepared from isolated
glomeruli. Cells were isolated and propagated as described
previously.11 Eight-micron, 24-well plate control inserts (BD
Bioscience, Bedford, MA) were coated overnight at 4C with
100 mL of 0.1% gelatin/PBS then washed 1 with PBS.
Mesangial cell cultures were incubated in 1% fetal calf serum
(FCS) overnight, then 0.05% bovine serum albumine
containing medium for at least 8 hours, washed 1with PBS,
and carefully trypsinized to ensure a single-cell suspension
and limited clumping of cells. After serum neutralization and
subsequent centrifugation, approximately 100,000 cells were
resuspended in 1.5 mL of 0.05% bovine serum albumin
medium containing inhibitors. The wells of a 24-well plate
were ﬁlled with 0.75 mL of 10% FCSecontaining medium
with inhibitors (excluding the 0.05% bovine serum albumin
control well). The cell suspension (0.05 mL) was loaded into
a gelatin-coated insert and the insert placed in a well. Wells
were visually inspected for bubbles beneath the insert and for
equal distribution of cell suspension. Cells were allowed to
migrate overnight (approximately 18 hours). Using a moist-
ened cotton swab, nonmigrated cells were liberated from the
apical side of the insert by gentle, but ﬁrm, rubbing. A second
swab repeated the removal and was followed by a single wash
with PBS. Inserts were ﬁxed, stained, and then washed (2)
in companion 24-well plate(s) containing 0.5mL ofmethanol,
0.5 mL of 1% toluidine blue in 1% borax, and 0.5 mL of
distilled water, respectively. Inserts were air dried and coun-
ted at 100 magniﬁcation. Five ﬁelds were counted on each
insert, including one center and four periphery areas. Data
were expressed as relative to the 10% FCS control well
(set equal to one). Inhibitors included 10 mmol/L ILK
inhibitor QLT-0267 (Valocor Therapeutics, Vancouver,
BC, Canada), 100 mmol/L Rac1 inhibitor NSC 23766
(Tocris Bioscience), or 1 mmol/L pan-AKT inhibitor, GSK
690693 (Tocris Bioscience).
Scratch Wound Migration Assay
For basal lamina studies, Superfrost Plus (VWR Interna-
tional, Radnor, PA) microscope slides were coated with the
following: 100 ng/mL Merosin (Millipore, Billerica, MA),
100 ng/mL human placental laminin (Sigma-Aldrich), 20
ng/mL human rlaminin-211 (BioLamina, Stockholm,
Sweden), or 20 ng/mL human rlaminin-521 (BioLamina)
per the manufacturer’s suggestion. Slide(s) were placed in
a tissue culture dish and an 8  8-mm cloning ring (Bellco
Glass, Vineland, NJ) placed on the coated area. A 100-mL
cell suspension (approximately 30,000 cells) in 1% fetal
bovine serumecontaining medium was added to the cloningThe American Journal of Pathology - ajp.amjpathol.orgring, and the cells were allowed to attach for approximately
8 hours; PBS was placed in the dish, and the ring was then
removed. An approximately 0.3- to 0.5-mm swath of cells
was removed by running a serological pipette at an
approximately 45 angle through the monolayer. After
capturing images of removed cells, slides were incubated for
24 hours in 1% fetal bovine serumecontaining medium,
washed with PBS, ﬁxed in methanol for 5 minutes, air dried,
and then stained for 30 minutes with modiﬁed Giemsa stain
(Sigma-Aldrich). Images of previously photographed ﬁelds
were captured using a Leica MZ10F microscope ﬁtted with
a Leica DFC310FX camera (Leica, Wetzlar, Germany).
Biomechanical Stretching of Cultured Mesangial Cells
Low-passage, subconﬂuent, primary mesangial cells were
trypsinized and seeded onto Bioﬂex 6-well plates (Flexcell
InternationalCorp.,Hillsborough,NC) coatedwith rat tail type I
collagen (BD Biosciences). Cells were plated in 5% FCSe
containing medium at densities that resulted in 20% to 40%
conﬂuence. The 0.5% FCSmedium was placed on the cells the
next day. Forty-eight hours later, the medium was changed and
the cultures exposed to a regimen of 60 cycles of stretch and
relaxation per minute with amplitude of 10% radial surface
elongation. The Flexercell Strain Unit FX4000 (Flexcell Inter-
national Corp.) was used to induce stretch/relaxation for 18
hours according to the manufacturer’s directions. Cells grown
identically, but not exposed to stretch, served as controls.
Real-Time Quantitative RT-PCR
Total RNA was reverse transcribed using SuperScript III
(Invitrogen; Life Technologies, Grand Island, NY) with
Oligo(dT)20 Primer (Invitrogen). Real-time PCR was per-
formed using TaqMan Gene Expression Master Mix
(Applied Biosystems; Life Technologies), and quantiﬁed
using ABI Prism 7000 sequence detection system (Applied
Biosystems). Samples were normalized to Mouse GAPDH
Endogenous Control VIC Probe (Applied Biosystems
catalog #4352339E), which was run alongside the CTGF
(Catalog #4331182, ID# Mm01192933_g1) and TGF-b1
(Catalog #4331182, ID# Mm01178820_m1) TaqMan Gene
Expression Assay Probes (Applied Biosystems). Each of the
samples was run in triplicate with a ﬁnal reaction volume of
50 mL and with the following cycling parameters: 50C for
2 minutes, 95C for 10 minutes, followed by 40 cycles of
a two-step PCR consisting of 95C for 15s and 60C for 1
minute. Relative changes in gene expression were deter-
mined by calculating the fold change using the comparative
CT method of 2
-DDCT following manufacturer’s instructions.
Activation of Mesangial Cell Cultures by Treatment
with Lipopolysaccharide
Subconﬂuent mesangial cells were trypsinized; plated at low
density on rat tail type 1 collagen (BD Biosciences) coated1271
Figure 1 Laminin 211 localizes to the GBM in Alport glomeruli. Dual
immunoﬂuorescence immunostaining was performed on wild-type (WT)
(AeC) and Alport (DeF) glomeruli from 7-week-old 129/Sv mice. GBM was
labeled with antielaminin a5 antibodies (red) and antielaminin a2 immu-
nostaining (green). Note the irregular deposits of laminin 211 in the Alport
GBM, especially in the thickened regions of the GBM. Scale bar Z 15 mm.
Zallocchi et alcytology slides (VWRInternational) and incubated overnight in
1% FCSecontaining medium. One hour after the addition of
serum-free medium, 50 mmol/L CDC42 inhibitor (ML141) or
10 mmol/L Rac-1 inhibitor NSC 23766 (Tocris Bioscience)
were added to individual slides and allowed to incubate for an
additional hour. Lipopolysaccharide (LPS) (10 ng/mL; Sigma-
Aldrich) was added to cells, incubated 1 hour, ﬁxed in ice-cold
acetone for 5minutes, and then allowed to air dry approximately
2 hours. Cells were stained with a 1:100 dilution of antibodies
speciﬁc for CDC42 (10155-1-AP; Proteintech, Chicago, IL),
and/or phalloidin (Molecular Probes; Life Sciences) washed,
and then imaged. Untreated, LPS alone and LPS plus inhibitor
treatments were repeated on two different derivations of
primary mesangial cells with qualitatively consistent results.
Pull-Down Assay
Pull-down experiments for Rac1 in mesangial cells were
done using the Rac1 Activation Assay Bicochem Kit
(BK035; Cytoskeleton, Denver, CO) and according to the
manufacturer’s instructions with minor modiﬁcations.
Brieﬂy, 500 to 800 mg of protein lysates were incubated with
20 mL of PAK-PBD beads for 1 hour at 4C. Pull-down
samples and total protein lysates (30 to 50 mg of protein) were
run in a 12% SDS-PAGE gel, transferred to polyvinylidene
diﬂuoride membranes, and then blocked in 5% milk for 30
minutes at room temperature. Rac-1 antibody incubation was
done overnight at 4C with rocking. After secondary anti-
body incubation and several washes, membranes were
developed using the ECL Plus kit (32134; Pierce Biotech-
nology, Rockford, IL) for pull-down experiments or the
SuperSignal West Femto kit (#34094; Pierce Biotechnology)
for total lysates. Films were exposed for 40 minutes and 5
minutes, respectively, and developed using a ﬁlm processor.
Confocal Microscopy
Slides were coverslipped using Vectashield mounting
medium containing DAPI to counterstain the nuclei (Vector
Laboratories) and confocal images captured using a Zeiss
AxioPlan 2IF MOT microscope interfaced with a LSM510
META confocal imaging system, using a 63 NA:1.4 oil
objective (Carl Zeiss, Oberkochen, Germany). Final ﬁgures
were assembled using Adobe Photoshop and Illustrator CS6
software (Adobe Systems, San Jose, CA).
Statistical Analysis
Data were analyzed using the Student’s t-test with Bonfer-
roni correction.
Results
GBM Laminin 211 in Alport Mice Is of Mesangial Origin
In the glomerulus, laminin 211 is normally found only in the
mesangial matrix. Figure 1, AeC, demonstrates mesangial1272distribution of laminin 211 in 7-week-old 129/Sv wild-type
mice, which is distinct from the glomerular basement
membrane (laminin a5). In Alport glomeruli (Figure 1, DeF),
irregular distribution of laminin 211 in theGBM,which appears
to accumulate preferentially in irregularly thickened regions of
the GBM (here, the GBM is marked by immunostaining with
antibodies speciﬁc for laminin a5), is observed. The cellular
source of the GBM laminin 211 has never been determined.
Dual immunoﬂuorescence labeling with antibodies against
laminin a2 and integrin a8 shows mesangial speciﬁc immu-
nostaining in wild-type glomeruli (Figure 2, AeC), as reported
previously.27 In Alport glomeruli (at 7 weeks of age), immu-
nostaining for both laminin a2 and integrin a8 appears to have
spread into the capillary loops, consistent with mesangial cell
process invasion of the capillary loops (Figure 2, DeF). Dual
immunoﬂuorescence immunostaining using the basement
membrane marker laminin a5 with the mesangial marker
integrin a8 conﬁrms that integrin a8 immunostaining, although
absent from the GBM in wild-type mice (Figure 2, GeI), is
clearly present in most of the GBM of Alport mice (Figure 2,
JeL). Transmission electron microscopy occasionally showed
the presence of mesangial processes in the glomerular capillary
loops ofAlport mice (Figure 2N), which are not observed in the
capillary loops from wild-type mice (Figure 2M). Collectively,
these data support that GBM laminin 211 arises from a mesan-
gial cell process invasion of the capillary loops, and thus is of
mesangial cell origin.
To determine the relevance of this observation to human
Alport syndrome, we stained cryosections from human
Alport necropsy kidney sections with antibodies speciﬁc for
integrin a8 and laminin a5. The results in Figure 3 show
that mesangial processes are clearly present adjacent to the
laminin a5-immunopositive GBM in the human specimen.
Mesangial Process Invasion of the Capillary Loops Is
Exacerbated by Elevated Biomechanical Strain
In an earlier report, we demonstrated that hypertension
exacerbated the progression of Alport glomerular disease.23ajp.amjpathol.org - The American Journal of Pathology
Figure 2 Mesangial processes invade the capillary loops of Alport
glomeruli where they colocalize with laminin 211 deposits. Dual immuno-
ﬂuorescence immunostaining was performed on wild-type (AeC and GeI) or
Alport (DeF and JeL) kidney sections from 7-week-old 129/Sv mice. Panels
show localization of laminin a2 (Lam a2) and integrin a8 (Int a8) (a
mesangial cell marker), and laminin a5 (a GBMmarker) and integrin a8. Note
circumferential colocalization of laminin a2 and integrin a8 in the Alport
glomerulus in DeF, and the colocalization of integrin a8 and laminin a5 in
JeL, indicating invasion of the glomerular capillary tufts with mesangial
processes. Scale barZ 10 mm (JeL); 5 mm (insets). Transmission electron
micrograph of a capillary loop from a 7-week-old wild-type (WT) mouse (M)
and an age-matched Alport mouse (N). Arrowheads denote extensions
coming from the interface of the mesangial cell with the glomerular capillary
loop, consistent with mesangial process invasion. Scale barZ 500 nm.
Figure 3 Mesangial processes invade the capillary loops of human Alport
glomeruli where they localize adjacent to laminin 521. Cryosections from
normal (AeC) and Alport (DeF) human kidneys were stained with antibodies
speciﬁc for laminin a5 (Lam a5) (green) and integrin a8 (Int a8) (red). The
integrin a8elabeled mesangial processes localize adjacent to the laminin
a5epositive GBM in human Alport, but not in normal human glomeruli,
consistent with mesangial process invasion. Scale barZ 15 mm.
Mesangial Processes in Alport PathologyHypertension accelerated several aspects of glomerular
disease progression, including proteinuria and induction of
matrix metalloproteinases. The accumulation of GBM
laminin 211 was also accelerated. In Figure 4, we show that
salt-induced hypertension clearly accelerates the inundation
of the glomerular capillary loops by mesangial processes, as
evidenced by the presence of integrin a8 immunopositivity
in the GBM (Figure 4, DeF).
We presume the increased biomechanical stress on the
glomerular capillary tuft in Alport glomeruli is due to the
change in GBM type IV composition from dual networks of
a1(IV)/a2(IV) and a3(IV)/a4(IV)/a5(IV) collagen to oneThe American Journal of Pathology - ajp.amjpathol.orgcomprising only a1(IV)/a2(IV) collagen. The latter is
thinner and known to contain fewer interchain disulﬁde
crosslinks,20 which would intuitively be expected to result
in increasing the elasticity of the glomerular ﬁltration
barrier. To provide independent validation of this assump-
tion, we examined a completely different model that would
also be expected to affect the elastic integrity of the
glomerular ﬁltration barrier, the CD151 knockout mouse.
CD151 is a tetraspanin co-receptor for integrin a3b1 that
functions to increase the afﬁnity of integrin a3b1 for its
GBM ligand, laminin a5.28 Deletion of CD151 results in
glomerular disease with morphological changes in the
GBM, strikingly similar to Alport syndrome.27 Therefore,
we examined glomeruli from the CD151 knockout mouse
for mesangial process invasion and laminin 211 deposition
in the GBM. The results in Figure 5 show a near complete
inundation of the glomerular capillary tufts with integrin a8
and laminin a2 immunopositivity in the CD151 knockout
mouse, demonstrating mesangial process invasion and
deposition of mesangial laminins in the GBM in this
genetically unrelated model.
If biomechanical strain can induce the activation of
mesangial process invasion of the capillary tuft, we should
be able to activate promigratory responses in vitro by
mechanically stretching cultured primary mesangial cells.
We subjected primary cultured mesangial cells, derived
from 129/Sv mice, to cyclic cell stretching using the Flex-
cell system for 18 hours. Expression of several promigratory
cytokines was quantiﬁed by real-time RT-PCR. The results
in Figure 6 demonstrate that expression of both TGF-b1 and
CTGF are signiﬁcantly elevated in cells subjected to
biomechanical stretching relative to cells cultured under
identical conditions, but not subjected to stretch. The data
represent two independent derivations of mesangial cells
with three independent stretch experiments where individual
treatment groups were run in triplicate.1273
Figure 4 Hypertension exacerbates mesangial invasion of the glomer-
ular capillary tufts in Alport mice. The X-linked Alport mouse model (on
C57Bl/6 background) was made hypertensive by providing L-NAME salts in
the drinking water from 5 weeks to 10 weeks of age. Control Alport mice
were given normal drinking water. Glomeruli were analyzed by dual
immunoﬂuorescence immunostaining using antibodies against laminin a2
(Lam a2) and integrin a8 (Int a8). Extensive mesangial process invasion of
the capillary tuft was observed in the glomeruli from the salt-treated mice
(DeF) relative to the mice given normal drinking water (AeC). Scale barZ
10 mm.
Figure 5 Extensive mesangial process invasion of the glomerular capillary
tufts is observed in CD151 knockout (KO) mice. Kidney cryosections from
8-week-old wild-type (WT) (AeC) and CDC151 KO mice (DeF) (on the FVB
background) were analyzed by dual immunoﬂuorescence immunostaining
using antibodies against laminin a2 and integrin a8. Extensive mesangial
process invasion of the capillary tuft was observed in the glomeruli from CD151
knockout mice relative to wild-type mice. Note that the extent of mesangial
process invasion in CD151 knockout mice is much greater than that observed
in Alport mice (Figure 2F). Scale barZ 15 mm.
Zallocchi et alIn Vitro Mesangial Cell Migration and in Vivo Mesangial
Process Invasion of the Glomerular Capillary Loops Are
Regulated by Integrin a1b1eMediated Rac1/CDC42
Activation
In earlier work, we demonstrated that deletion of integrin a1
markedly attenuated the progression of glomerular disease
in Alport mice.8 Although it is highly likely that disease
attenuation in integrin a1enull Alport mice emanates from
the mesangial compartment where integrin a1b1 is highly
expressed, the molecular mechanism underlying this effect
has remained unclear. In Figure 7, we show that deletion of
integrin a1 reduces the dynamics of mesangial process
invasion of the capillary tufts in Alport mice, consistent with
the reduction in GBM laminin 211 deposition shown here
and previously.8
Because it is well established that the formation of ﬁlo-
podia and lamellipodia requires the concerted action of the
small GTPases Rac1 and CDC42,29 we performed cell
migration assays using the Boyden chamber approach to
determine whether such a functional connection was evident
in cultured wild-type and integrin a1enull mesangial cells.
The results in Figure 8A show that integrin a1enull
mesangial cells show a signiﬁcant reduction in migratory
potential relative to wild-type mesangial cells. Migration of
wild-type cells was signiﬁcantly reduced when cells were
treated with either the integrin-linked kinase inhibitor QLT-
0267, or the Rac1 inhibitor NSC 23766. Cell migration of
wild-type cells was not affected by treatment with the pan
AKT inhibitor GSK 690693. Integrin a1enull mesangial
cell migration was not affected by treatment of cells with
Rac1 inhibitors (data not shown), suggesting that deletion of
integrin a1 abrogates Rac1-dependent cell migration.1274Treatment of cells with the bacterial endotoxin LPS
activates both Rac1 and CDC42 GTPases,30,31 and is known
to induce the formation of both lamellipodia and ﬁlopodia in
cultured mesangial cells.32 We treated cultured wild-type
mesangial cells with LPS, stained the actin ﬁlaments with
phalloidin, and examined the cultures for morphological
changes. As shown in Figure 8, BeE, after 30 minutes,
treated cells underwent a stark morphological change: about
half of the cells sprouted numerous ﬁlopodia (Figure 8C)
that were easily identiﬁed by a blinded observer (D.C.) in at
least ﬁve replicate experiments. Cells treated with LPS in
combination with either the Rac1 inhibitor NSC 23766 or
the CDC42 inhibitor ML 141 could not be distinguished in
blinded experiments from untreated wild-type mesangial
cells (Figure 8, D and E, respectively). Interestingly, treat-
ment of integrin a1enull mesangial cells with LPS had no
discernible effect on cell morphology (data not shown). To
further validate these ﬁndings, we stimulated either wild-
type or a1-null mesangial cell cultures with LPS in the
presence or absence of either Rac1 or CDC42 inhibitors and
performed immunoﬂuorescence analysis for CDC42 locali-
zation and pull-down assays for activated Rac1. As shown
in Figure 8, FeI, treatment of cells with LPS resulted in
polarized localization of CDC42 associated with staining in
adjacent ﬁlopodia (Figure 8G), an established characteristic
of CDC42 activation.33,34 Treatment of these cells with
Rac1 inhibitor abolished this polarized activation, indicating
crosstalk between Rac1 and CDC42 (Figure 8H). Integrin
a1enull mesangial cells did not respond to LPS activation
with polarized CDC42 localization (data not shown). Pull
down assays demonstrate that LPS treatment does indeed
activate Rac1, and that pretreatment of cells with the Rac1
inhibitor abolishes its activation (Figure 8I). Interestingly,
pretreatment of cells with CDC42 inhibitors did not blockajp.amjpathol.org - The American Journal of Pathology
Figure 6 Biomechanical stretching of cultured primary mesangial cells
induces expression of promigratory cytokines, CTGF (white bars) and TGF-b1
(black bars) mRNA. Two independent derivations of primary mesangial cell
cultures from wild-type mice were subjected to cyclic biomechanical
stretching for 18 hours. RNA from multiple stretch experiments, which were
run in triplicate, were analyzed by quantitative real-time RT-PCR for CTGF
and TGF-b1 mRNA. Statistically signiﬁcant increases in expression for both
cytokines were observed. *P < 0.05.
Figure 7 Integrin a1 deletion in Alport mice results in markedly
reduced mesangial process invasion of the glomerular capillary tufts.
Glomeruli from 7-week-old integrin a1enull mice (AeC), Alport mice
(DeF), and integrin a1enull Alport mice (DKO) on 129/Sv background
mice (GeI) were analyzed by dual immunoﬂuorescence immunostaining
using antibodies against laminin a2 (Lam a2) and integrin a8 (Int a8). The
degree of mesangial process invasion of the glomerular capillary tufts is
greatly reduced in the integrin a1enull Alport mice relative to age/strain-
matched Alport mice. Scale bars: 10 mm (AeI); 5 mm (insets, DeF).
Mesangial Processes in Alport PathologyLPS-mediated Rac1 activation, suggesting that, whereas
Rac1 inhibitors block LPS-mediated CDC42 activation
(Figure 8H), CDC42 inhibitors do not block Rac1 activation
(Figure 8I).
To examine the effect of Rac1 inhibitors on Alport
glomerular disease progression, we treated Alport mice with
inhibitors by i.p. injection from 2 weeks to 6 weeks of age.
Glomeruli were examined for mesangial process invasion of
the capillary tufts by dual immunoﬂuorescence microscopy
using antibodies speciﬁc for either integrin a8 or the GBM
marker laminin a5. The results in Figure 9 demonstrate that
saline-injected mice show signiﬁcant colocalization of
integrin a8 and laminin a5 throughout many of the
glomerular capillary tufts, whereas mice injected with the
Rac1 inhibitor showed very little mesangial process inva-
sion. Combined, the data in Figures 7, 8, and 9 conﬁrm that
mesangial process invasion of the glomerular capillaries is
a Rac1-dependent process, and is attenuated by integrin a1
deletion in vivo. Furthermore, LPS activation of ﬁlopodia in
wild-type mesangial cells (but not in a1-null mesangial
cells) involves both Rac1 and CDC42 activation, suggesting
integrin a1b1edependent crosstalk between the two small
GTPases in the signaling complex.
Laminin 211 Enhances Mesangial Cell Migration and
Mesangial Process Invasion of the Capillary Loops
We crossed laminin a2edeﬁcient mouse with the Alport
mouse to produce a double knockout. One effect of laminin
a2 deﬁciency was a marked reduction of mesangial process
invasion of the capillary loops (Figure 10, AeC). We inter-
preted this to mean that laminin 211 might facilitate mesan-
gial process invasion of the capillary loops. To test this
theory, we performed cell migration assays on either laminin
211 or laminin 521 (GBM laminin). Two different laminin
preparations were used. One was extracted laminin from
either placenta (primarily laminin 511) or muscle (primarilyThe American Journal of Pathology - ajp.amjpathol.orglaminin 211); the other preparation, commercially available
puriﬁed recombinant laminin heterotrimers. A scratch wound
assay was used as opposed to the Boyden chamber because
here, we are looking at the role of speciﬁc extracellular matrix
in potentiating mesangial cell migration. As shown in
Figure 10, DeG, wild-type mesangial cells migrate much
more efﬁciently on laminin 211 compared to laminin 521.
The effect was more pronounced on the muscle laminin
preparation relative to the placental laminin preparation; it
was also clear on the pure recombinant laminin substrates. To
more directly conﬁrm the role of laminin a2 in migratory
potential, we measured the relative migration of wild-type
mesangial cells to mesangial cells derived from laminin
a2edeﬁcient mice, using the Boyden chamber approach. The
results in Figure 10H demonstrate a statistically signiﬁcant
reduction in the migratory potential of laminin a2edeﬁcient
mesangial cells relative to wild-type mesangial cells, based
on analysis of three independent derivations run in triplicate
(P < 0.001). Collectively, the data in Figure 10 suggest that
laminin 211 deposition by the mesangial processes func-
tionally contributes to the process invasion of the capillary
tuft in Alport (and CD151-knockout) glomeruli.
Discussion
Earlier studies of Alport mouse, dog, and humans reported
the presence of abnormal laminins in the GBM, including
laminin 211 and laminin 111.8,13,19 These laminins tend to1275
Zallocchi et alaccumulate in areas of irregular thickening of the GBM, and
these thickened areas have been shown to be more perme-
able to ferritin, suggesting that they comprise loosely
assembled or partially degraded extracellular matrix.35 In1276addition to the abnormal laminins, ﬁbronectin has also been
reported to accumulate in the GBM of Alport mice.15 These
glomerular ECM components are normally found in the
mesangial matrix,36 suggesting that the abnormal GBM
matrix molecules that progressively accumulate in the
Alport GBM may be of mesangial cell origin. Here, we used
integrin a8 as a speciﬁc mesangial cell surface marker to
demonstrate that mesangial processes invade the capillary
tufts and colocalize with laminin 211, a mesangial laminin.
Integrin a8 is expressed in mesangial cells, but not in other
glomerular cell types,27 and its expression is generally
restricted to smooth muscle cells and neuronal cell
types.37,38 Mesangial process invasion of the glomerular
capillary tufts was exacerbated by hypertension, suggesting
that the mechanism triggering this event was mediated by
biomechanical stress, likely at the interface between the
mesangial processes and the subendothelial interface with
the glomerular capillaries, an area known to provide
important structural support for the capillary loops.36 The
Alport mutations result in the absence of the collagen
a3(IV)/a4(IV)/a5(IV) network from the GBM. The conse-
quence is a thinner GBM comprising only a1(IV) and
a2(IV) collagens, which have been shown to contain fewer
interchain disulﬁde crosslinks.20 This structural change
would be predicted to alter the biomechanical properties of
the capillary tuft, resulting in stresses on the cells
comprising the tuft even under normal glomerular blood
pressures. We examined a second model, the CD151
knockout mouse, which would also be expected to show
enhanced strain on the capillary tufts. In this model,
enhanced strain arises as a result of reduced adhesion of the
podocyte pedicles to the GBM due to reduced afﬁnity forFigure 8 Integrin a1b1edependent Rac1/CDC42 activation mediates
dynamic remodeling of the actin cytoskeleton in cultured primary mesan-
gial cells (MES). A: Migration of primary cultured mesangial cells is
signiﬁcantly reduced under conditions of integrin a1 deletion, integrin-
linked kinase inhibition, Rac1 inhibition, but not AKT inhibition. Migra-
tion was measured by Boyden chamber assay in the presence or absence of
the ILK inhibitor QLT-0267 (QLT), the Rac1 inhibitor NSC 23766, or the pan-
AKT inhibitor GSK 690693, and for integrin a1enull mesangial cells (Ia1
Null MES). Multiple replicate experiments were performed on multiple
independent derivations of mesangial cells and the data analyzed by
Student’s t-test. *P < 0.05 versus 10% FCS alone. BSA, bovine serum
albumin. BeE: Treatment of cultured mesangial cells with LPS induced
cytoskeletal rearrangement with numerous actin spikes (asterisks in C), as
determined by phalloidin staining (untreated cells, B; LPS-treated cells, C),
and these morphological changes were blocked by treatment of cells with
either Rac1 inhibitors (D) or CDC42 inhibitors (E). Untreated integrin
a1enull cells did not respond to LPS treatment (data not shown). FeI:
Treatment of cultured mesangial cells with LPS results in polarized locali-
zation of CDC42 (red) and is associated with ﬁlopodia (phalloidin in green)
(G, inset), compared to Golgi and cytosolic localization of CDC42 in wild-
type cells (F). Pretreatment of cells with the Rac1 inhibitor NSC 23766
abolished LPS-activated polarized localization of CDC42 (H), indicating
crosstalk between Rac1 and CDC42. I: GTP-Rac1 pull-down assay conﬁrms
LPS-mediated activation of Rac1 in cultured mesangial cells is blocked by
pretreatment with Rac1 inhibitors, but not by CDC42 inhibitor. Scale bars:
12 mm (BeH); 6 mm (inset, G). Cont, control; inh, inhibitor; lys, lysates.
ajp.amjpathol.org - The American Journal of Pathology
Figure 10 Laminin 211 potentiates mesangial process invasion of the
glomerular capillary loops in Alport mice and promotes mesangial cell
migration in vitro. AeC: Laminin a2edeﬁcient Alport mice on 129/Sv
background show reduced mesangial process invasion of the glomerular
capillary tufts. Cryosections of kidney tissue from 8-week-old laminin
a2edeﬁcient Alport mice were analyzed by dual immunoﬂuorescence im-
munostaining using antibodies against laminin a5 and integrin a8. The
degree of mesangial process invasion of the glomerular capillary tufts is
greatly reduced in the laminin a2enull Alport mice relative to Alport mice
(compare with Figure 2, JeL). DeG: Wild-type mesangial cells migrate more
robustly on laminin 211 compared to laminin 521 (GBM laminin). Wound
scratch assays were performed using wild-type mesangial cells cultured on
either recombinant puriﬁed laminins or commercially available laminins
extracted from either placenta (primarily laminin 511) or muscle (primarily
laminin 211). Images shown are representative of multiple replicates. H:
Primary mesangial cells from laminin a2edeﬁcient mice (1 dY MES) show
impaired migratory potential relative to wild-type mesangial cells (1 WT
MES). Boyden chamber assays were performed. Blinded cell counts from
multiple replicates were analyzed. ***P < 0.001. Scale barZ 10 mm.
Figure 9 Treatment of Alport mice with Rac1 inhibitors partially
ameliorates mesangial cell process invasion of the glomerular capillary
tufts. Alport mice on 129/Sv background were injected once daily with
either saline (AeC) or the Rac1 inhibitor NSC 23766 (DeF) from 2 weeks to
6 weeks of age. Kidney cryosections were analyzed by dual immunoﬂuo-
rescence immunostaining using antibodies against either laminin a2 (Lam
a2) or integrin a8 (Int a8). The degree of mesangial process invasion of
the glomerular capillary tufts is ameliorated in the Rac1 inhibitore
treated mice relative to mice injected with saline. Scale bar Z 15 mm.
Original magniﬁcation, 7.5 mm (insets).
Mesangial Processes in Alport Pathologythe podocyte integrin a3b1 for its GBM ligand laminin
521.28 Mesangial process invasion of the glomerular capil-
lary tufts in the CD151 mouse was even more robust than
that for the Alport model. Like the Alport model,23
glomerular pathology in the CD151 mouse model, which
shows ultrastructural lesions in the GBM strikingly similar
to Alport syndrome,39,40 is signiﬁcantly exacerbated under
hypertensive conditions.24 Collectively, this evidence
supports the notion that mutations affecting structural
integrity of the glomerular capillary tuft result in unnatural
stresses on the cells in contact with the tuft. In the mesangial
cell compartment, this results in mesangial process invasion
into the tuft and deposition of matrix proteins in the GBM
that are of mesangial cell origin.
In earlier work, we showed that deletion of the mesangial
integrin a1b1 in Alport mice resulted in a marked attenua-
tion in the progression of the glomerular pathology, with
reduced proteinuria and a near doubling of lifespan.8 The
mechanism underlying the inﬂuence of mesangial integrin
a1b1 on Alport renal disease progression has, until now,
remained unclear. In this study, we show that mesangial
process invasion is markedly attenuated in integrin a1enull
Alport mice relative to strain/age-matched Alport mice. This
observation suggested that the signaling pathway that acti-
vates actin cytoskeletal rearrangements is perturbed in the
absence of integrin a1b1. Consistent with this notion, we
observed decreased migratory potential for primary cultures
of a1-null mesangial cells relative to wild-type mesangial
cells from strain/age-matched mice (Figure 8A). LPS, which
activates both Rac1 and CDC42 in wild-type mesangial
cells (Figure 8, BeE), failed to activate Rac1 or CDC42,
and failed to activate actin cytoskeletal rearrangements in
cultured a1-null mesangial cells (data not shown). Collec-
tively, these data support a mechanism that might explain
why deletion of integrin a1 results in attenuation of Alport
glomerular pathogenesis, where integrin a1b1 is a keyThe American Journal of Pathology - ajp.amjpathol.orgsensor of biomechanical strain at the glomerular capillary
tuft, and participates in the adhesive signaling mechanism
that links to the Rho GTPases Rac1 and CDC42, which
activate actin polymerization dynamics required to process
invasion of the glomerular capillary tufts. In addition to
integrin a1b1, the collagen receptor discoidin domain
receptor tyrosine kinase 1 (DDR1) has been functionally
linked to mesangial cell migration and adhesion of mesan-
gial cells,41 and deletion of DDR1 slows the progression of
renal disease in Alport mice.42 These observations suggest1277
Zallocchi et althat DDR1 may have functions in the mesangial cell
compartment that are similar to that of integrin a1b1. The
link between integrin adhesion, ILK signaling, and activa-
tion of Rac1-mediated cytoskeletal rearrangements has been
described previously.43 In an earlier report, Gross et al44
demonstrated a strong nephroprotective effect for the
angiotensin-converting enzyme inhibitor ramipril in the
129/Sv autosomal Alport mouse model, an observation that
has recently been extended to humans with Alport
syndrome.45 These investigators were not able to fully
explain the nephroprotective effect of angiotensin-converting
enzyme inhibition by its antihypertensive and antiproteinuric
inﬂuences. It is possible that the effect of angiotensin-
converting enzyme inhibition on the mesangial compart-
ment might confer this additional therapeutic beneﬁt.
Classically, Rac1 activation is associated with lamelli-
podia formation, and CDC42 activation is associated with
ﬁlopodia formation.46 Recently, evidence for crosstalk
between the two Rho GTPases has emerged.47 This
phenomenon is likely regulated through the guanine
nucleotide exchange factor b1pix, which contains binding
sites for both CDC42 and Rac1.48,49 Here, we provide
evidence for crosstalk between Rac1 and CDC42 in
cultured mesangial cells regulating actin cytoskeletal
rearrangement including: i) treatment of mesangial cells
with LPS, known to activate rapid actin cytoskeletal
rearrangement,32 activates Rac1 in wild-type mesangial
cells (Figure 8I); ii) membrane localization of CDC42,
a known prerequisite for its activation,50,51 is blocked by
addition of RAC1 inhibitor coincident with LPS stimula-
tion (Figure 8, FeI); and iii) inclusion of either Rac1
inhibitor or CDC42 inhibitor on stimulation of mesangial
cell cultures with LPS blocks actin cytoskeletal rear-
rangements (Figure 8, BeE).
Mesangial cell cultures subjected to cyclic biomechanical
strain expressed elevated levels of the promigratory cyto-
kines CTGF and TGF-b1, providing further evidence that
biomechanical strain could activate actin cytoskeletal
dynamics required for mesangial process invasion. Both
CTGF and TGF-b1 signaling have been shown to activate
CDC42,52,53 and both cytokines have been shown to be
induced in Alport glomeruli,7,13 suggesting that activation
of these signaling pathways might be an important under-
lying mechanism for the activation of mesangial process
invasion of glomerular capillary tufts in Alport syndrome.
Indeed, earlier work from our laboratory showed that inhi-
bition of TGF-b1 in the Alport mouse resulted in abrogation
of GBM thickening, in support of this notion.8 We also
showed that when TGF-b1 was inhibited in integrin
a1enull Alport mice, a synergistic improvement in
glomerular disease was observed, suggesting that TGF-b1
and integrin a1 are working through distinct pathways. On
the basis of the current study, these pathways may converge
on strain-mediated activation of Rac1/CDC42 in the
mesangial cell compartment. Although the deposition of
laminin 211 in the GBM of Alport mice was described more1278than 10 years ago,8,13 a functional role for laminin 211 in
Alport glomerular pathology has not been described. We
show reduced mesangial process invasion of the glomerular
capillary loops in Alport mice that are also lacking laminin
a2, suggesting that laminin 211 itself promotes the migra-
tion of processes into the glomerular capillary loops
(Figure 10, AeC). Consistently, we show that wild-type
mesangial cells migrate more robustly when cultured on
laminin 211 compared to laminin 521, and that primary
mesangial cells from laminin a2edeﬁcient mice show
impaired migration relative to primary wild-type mesangial
cells from age/strain-matched mice (Figure 10, DeH).
Although modulation of mesangial cell migration by ECM
has been described previously,54 these data suggest that the
strain-mediated mesangial process invasion of the capillary
loops is enhanced by mesangial cellesecreted laminin 211,
which may explain why laminin 211 accumulates in the
patchy, irregularly thickened regions of the Alport GBM
(see Figure 1).
Our data suggest that the changes in the biophysical
properties of the Alport glomerular capillary tuft result in
biomechanical stresses that result in the induction of path-
ological processes. Parallel observations in Alport and
CD151 mouse models, including mesangial process inva-
sion of the glomerular capillary tufts and deposition of
laminin 211, provide strong support for this notion, because
the two mouse models arise from mutations that would be
expected to relax the structural integrity of the glomerular
capillary tufts, but are otherwise mechanistically unrelated
to each other. Recent studies of the biophysical properties
of Alport glomeruli from pre-proteinuric mice reported
increased deformability.22 Collectively, our current work
suggests a model where biomechanical stresses on the
glomerular capillary tufts activate a promigratory signaling
cascade in mesangial cells involving integrin a1b1e
mediated activation of Rac1/CDC42. This activation
culminates in the invasion of the capillary loops by
mesangial processes. These processes clearly deposit lam-
inin 211, which further exacerbates the mesangial process
invasion. In addition to laminin 211, other mesangial
matrix molecules are likely deposited in the GBM, and
local action of mesangial cytokines (TGF-b1 and CTGF,
for example) and MMPs might also contribute to the
structural and functional properties of the Alport GBM
(irregular thickening, splitting, permeability, and so on). In
addition, all of these events are very likely to inﬂuence
podocyte cell health. Therefore, we conclude that mesan-
gial process invasion of the GBM is an important early
event that precipitates glomerulosclerosis in Alport
syndrome. The fact that we observe mesangial process
invasion of glomerular capillary loops in human Alport
glomeruli provides relevance for these observations to the
human disease. A better understanding of the activation
process might reveal novel targets capable of preventing
this event and arresting the Alport glomerular pathogenesis
in its pre-initiated state.ajp.amjpathol.org - The American Journal of Pathology
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